Trial
NCT01598168
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
McMaster University
Collaborators
—
Condition
Heparin-induced Thrombocytopenia
Intervention
Rivaroxaban
Why stopped
slow recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-03-25